Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
[ad_1] News of the Successful Trial Comes Amid an Oversubscribed Investor Round and Preparation for Series A Financing Round RALEIGH, N.C., February 8, 2024 (Newswire.com) – Belhaven Biopharma, a leader in innovative treatments for severe allergic reactions, today shared promising results from its Phase 1 clinical trial of Nasdepi, a nasal dry powder epinephrine device […]